Graham Michael Wynne
Graham Michael Wynne, Oxfordshire GB
Patent application number | Description | Published |
---|---|---|
20100317607 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS - Compounds of a compound of compound of general formula (I) wherein X | 12-16-2010 |
20110195932 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy - Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations. | 08-11-2011 |
20120020950 | ANTIBACTERIAL COMPOUNDS - Disclosed are compounds of formula (I), which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, | 01-26-2012 |
Graham Michael Wynne, Abingdon GB
Patent application number | Description | Published |
---|---|---|
20100022613 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (I) | 01-28-2010 |
20100035956 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (I) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis. | 02-11-2010 |
20100168072 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy - Combinations comprising (or consisting essentially of) one or more compounds of the formula (I) or (II) with one or more ancillary compounds, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations. | 07-01-2010 |
20100305120 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY - Compounds of formula (I): wherein X, L | 12-02-2010 |
Graham Michael Wynne, Oxon GB
Patent application number | Description | Published |
---|---|---|
20090186923 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (I) | 07-23-2009 |
20090192195 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (I) | 07-30-2009 |
20100063103 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (I) | 03-11-2010 |
20100266535 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (II) | 10-21-2010 |
20110123547 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (II) | 05-26-2011 |
20110142855 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (I) | 06-16-2011 |
20140039012 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (II) | 02-06-2014 |
Graham Michael Wynne, Bicester GB
Patent application number | Description | Published |
---|---|---|
20090075938 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - There are disclosed compound of Formula (1): A | 03-19-2009 |
20100048660 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - There are disclosed compound of Formula (I) or (II) wherein A | 02-25-2010 |
20110195929 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS - Described are various compounds and methods for the treatment of flaviviral infections. In particular, alkaloids and imino sugars in arabinose and/or lyxose stereochemical configuration with antiflaviviral activity are described. | 08-11-2011 |
20110237538 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES - Described are various compounds, in particular iminosugars, and methods for the treatment of proteostatic diseases, in particular lysosomal storage disorders. The compound may be a pharmacoperone of an enzyme selected from: (a) Acid alpha-glucosidase; (b) Acid beta-glucosidase; (c) glucocerebrosidase; (d) alpha-Galactosidase A; (e) Acid beta-galactosidase; (f) beta-Hexosaminidase A; (g) beta-Hexosaminidase B; (h) Acid sphingomyelinase; (i) Galactocerebrosidase; (j) Acid ceramidase; (k) Arylsulfatase A; (l) alpha-L-Iduronidase; (m) Iduronate-2-sulfatase; (n) Heparan N-sulfatase; (o) alpha-N-Acetylglucosaminidase; (p) Acetyl-CoA: alpha-glucosaminide N-acetyltransferase; (q) N-Acetylglucosamine-6-sulfate sulfatase; (r) N-Acetylgalactosamine-6-sulfate sulfatase; (s) Acid beta-galactosidase; (t) Arylsulfatase B; (u) beta-Glucuronidase; (v) Acid alpha-mannosidase; (w) Acid beta-mannosidase; (x) Acid alpha-L-fucosidase; (y) Sialidase; and (z) alpha-N-acetylgalactosaminidase. | 09-29-2011 |
20110268693 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (I) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis. | 11-03-2011 |
20140018320 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - There are disclosed compound of Formula (1): A | 01-16-2014 |
Graham Michael Wynne US
Patent application number | Description | Published |
---|---|---|
20120149741 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - There are provided compounds of Formula (I) wherein three of A | 06-14-2012 |
Graham Michael Wynne, Oxford GB
Patent application number | Description | Published |
---|---|---|
20140378451 | Cannabinoid-2-Receptor Agonists - The present invention relates to cannabinoid-2-receptor (CB2R) agonist compounds. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them and to their use as therapeutic agents for the treatment and/or prevention of diseases or conditions in which CB2R stimulation is beneficial (especially inflammatory conditions). | 12-25-2014 |